Jacob J. Orme, MD, PhD
Mayo Clinic · Mayo Clinic in Rochester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jacob J. Orme, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07087860 · Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersMayo Clinic · recruiting · Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma · principal investigator
- Ph4NCT06764095 · Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialMayo Clinic · recruiting · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma · principal investigator
- Ph2NCT06378866 · Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialMayo Clinic · recruiting · Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Novel ctDNA biomarker for androgen therapy in metastatic prostate cancerR01CA286127 · NCI · WASHINGTON UNIVERSITY · PI Aadel Chaudhuri, Christopher A Maher, Russell K. Pachynski · fiscal years 2024 to 2026Named on NCT06378866
- Blood-based tumor and immune markers for risk stratification and monitoring treatment response in oligometastatic prostate cancerR01CA300454 · NCI · MAYO CLINIC ROCHESTER · PI Aadel Chaudhuri, Fabrice Lucien-Matteoni, Sean S Park · fiscal years 2026Named on NCT06378866
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.